Provided herein are methods, systems and kits for use in identifying a subject with an increased risk of developing severe forms of inflammatory bowel disease (IBD), based at least in part, on an expression of one or more biomarkers detected in a biological sample obtained from the subject. Also provided are methods, systems and kits for treating, or optimizing the treatment for, the IBD based, at least in part, on the expression the one or more biomarkers. In some embodiments, the one or more biomarkers is angiotensin-converting enzyme 2 (ACE2), the host receptor for severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2).
DYSREGULATION OF COVID-19 RECEPTOR ASSOCIATED WITH IBD